Nisa Investment Advisors
HUMA icon

Nisa Investment Advisors’s Humacyte HUMA Stock Holding History

Nisa Investment Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$592 Buy
758
+115
+18% +$107 ﹤0.01% 2918
2026
Q1 		$390 Buy
+643
New +$668 ﹤0.01% 2892
2025
Q4 		– Sell
-351
Closed -$611 – 3017
2025
Q3 		$611 Sell
351
-123
-26% -$241 ﹤0.01% 2822
2025
Q2 		$991 Sell
474
-221
-32% -$425 ﹤0.01% 2740
2025
Q1 		$1.19K Buy
695
+587
+544% +$2.2K ﹤0.01% 2591
2024
Q4 		$545 Sell
108
-56
-34% -$277 ﹤0.01% 2818
2024
Q3 		$892 Sell
164
-38
-19% -$251 ﹤0.01% 2606
2024
Q2 		$970 Buy
202
+80
+66% +$416 ﹤0.01% 2527
2024
Q1 		$379 Buy
122
+28
+30% +$94 ﹤0.01% 2547
2023
Q4 		$267 Sell
94
-16,006
-99% -$41.1K ﹤0.01% 2514
2023
Q3 		$47.2K Buy
16,100
+7,260
+82% +$24K ﹤0.01% 1740
2023
Q2 		$25.3K Buy
8,840
+4,440
+101% +$16K ﹤0.01% 2016
2023
Q1 		$14K Buy
4,400
+4,300
+4,300% +$12.2K ﹤0.01% 2095
2022
Q4 		$0 Buy
+100
New +$304 ﹤0.01% 2632

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nisa Investment Advisors's HUMA Position: Q2 2026 in Review

Nisa Investment Advisors increased its Humacyte (HUMA) stake by 18% in Q2 2026, buying an estimated $107 and bringing the position to 758 shares worth $592. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Nisa Investment Advisors first reported a position in HUMA in Q4 2022 and has held it in 14 quarters since. The position peaked at $47.2K in Q3 2023. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Nisa Investment Advisors held 758 shares of Humacyte worth $592 as of Q2 2026.
  • Nisa Investment Advisors bought 115 Humacyte shares in Q2 2026, an estimated $107.
  • Humacyte made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2918 holding.
  • Nisa Investment Advisors first reported a position in Humacyte in Q4 2022 and has held it in 14 quarters since.
  • Nisa Investment Advisors's Humacyte position peaked at $47.2K in Q3 2023.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.